-transparent.png){kind=logo}
The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharmacokinetics observed in 6 patients treated with amphotericin B deoxycholate at the standard dose of 1.0 mg/kg. Interpatient variabilities of amphotericin B peak concentrations (Cmax) and areas under concentration-time curves (AUC) were 8- to 10-fold greater for patients treated with AmBisome than for patients treated with amphotericin B deoxycholate. At the threefold greater dose of AmBisome, median Cmaxs were 8.4-fold higher (14.4 versus 1.7 microg/ml) and median AUCs exceeded those observed with amphotericin B deoxycholate by 9-fold. This was in part explained by a 5.7-fold lower volume of distribution (0.42 liters/kg) in AmBisome-treated patients. The elimination of amphotericin B from serum was biphasic for both formulations. However, the apparent half-life of elimination was twofold shorter for AmBisome (P = 0.03). Neither hemodialysis nor hemofiltration had a significant impact on AmBisome pharmacokinetics as analyzed in one patient. In conclusion, the liposomal formulation of amphotericin B significantly (P = 0.001) reduces the volume of drug distribution, thereby allowing for greater drug concentrations in serum. The low toxicity of AmBisome therefore cannot readily be explained by its serum pharmacokinetics.
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
May 1994,
The Journal of infection,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
November 1993,
Drug and therapeutics bulletin,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
June 2012,
Journal of clinical pharmacy and therapeutics,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
January 1994,
Bone marrow transplantation,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
March 2002,
Antimicrobial agents and chemotherapy,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
May 2008,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
July 1998,
Journal of clinical pharmacology,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
October 2022,
Medical mycology,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
April 1994,
Antimicrobial agents and chemotherapy,
V Heinemann, and
D Bosse, and
U Jehn, and
B Kähny, and
K Wachholz, and
A Debus, and
P Scholz, and
H J Kolb, and
W Wilmanns
August 2012,
Harefuah,
